Loading...
•
Sep 30
Immuneering Q3 2025 Earnings Report
Immuneering reported a net loss of $15.0 million in Q3 2025 with cash reserves significantly boosted to $227.6 million following financing activities.
Key Takeaways
Immuneering ended Q3 2025 with strong financial backing from recent funding and reported continued investment in R&D for its lead oncology programs, despite posting a net loss.
Raised $225 million in financing, extending cash runway into 2029
Reported 86% 9-month overall survival in pancreatic cancer patients treated with atebimetinib + mGnP
Q3 net loss totaled $15.0 million, or $0.38 per share
Cash and cash equivalents rose to $227.6 million from $36.1 million at year-end 2024
Immuneering
Immuneering
Forward Guidance
Immuneering expects to begin dosing patients in its pivotal Phase 3 trial of atebimetinib + mGnP by mid-2026, with updated survival data anticipated in the first half of 2026.
Positive Outlook
- Cash runway extended into 2029
- Phase 3 trial of atebimetinib + mGnP to start mid-2026
- Updated survival data expected in 1H 2026
- Regulatory feedback on pivotal trial expected in Q4 2025
- Ongoing strong responses in pancreatic cancer patients support clinical strategy
Challenges Ahead
- Continued net losses due to R&D investment
- No reported revenue in the current quarter
- Dependence on successful atebimetinib trial outcomes
- Uncertainty around future regulatory approvals
- Ongoing high operating expenses impacting profitability